Evaluation of adverse events associated with antiretroviral therapy and the relationship to treatment adherence

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 2, 2013, Pages 141-146

  Lenzi, Luana ^a   Wiens, Astrid ^a   Pontarolo, Roberto ^a,b  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b Prefeito Lothário Meissner ^*  (Brazil)

Author keywords

Antiretroviral; Medication adherence; Patient care

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ALCOHOL INTOXICATION; ALLERGIC REACTION; ALLERGY; ANEMIA; ARTICLE; ATOPY; CHRONIC DIARRHEA; CONTROLLED STUDY; DEPRESSION; DISCOID MACULAR RASH; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; DYSLIPIDEMIA; DYSPEPSIA; EPIGASTRIC PAIN; FEMALE; GASTRITIS; GASTROINTESTINAL DISEASE; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; INCIDENCE; JAUNDICE; KIDNEY FAILURE; LIPOATROPHY; LIPODYSTROPHY; LIVER TOXICITY; MACULAR RASH; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; NEUROLOGIC DISEASE; NIGHTMARE; OBSERVATIONAL STUDY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHOTODERMATOSIS; RETROSPECTIVE STUDY; SOMNOLENCE; TASTE DISORDER; TREATMENT RESPONSE; VOMITING;

ANEMIA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAZIL; FEMALE; GASTROINTESTINAL DISEASES; HIV INFECTIONS; HUMANS; LIPODYSTROPHY; MALE; MEDICATION ADHERENCE; PANCREATITIS; PERIPHERAL NERVOUS SYSTEM DISEASES; PROTEASE INHIBITORS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SKIN DISEASES;

EID: 84873834562     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201818     Document Type: Article

References (19)

1. Wood R, Phanuphak P, Cahn P, Pokrovskiy V, Rozenbaum W, Pantaleo G, Sension M, Murphy R, Mancini M, Kelleher T, Giordano M. Longterm efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr. 2004; 36: 684-692. doi:10.1097/00126334-200406010-00005 PubMed
2. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD; HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006; 43: 27-34. doi:10.1097/01.qai.0000233310.90484.16 PubMed
3. Röling J, Schmid H, Fischereder M, Draenert R, Goebel FD. HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis. 2006; 42: 1488-1495. doi:10.1086/503566 PubMed
4. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S et al; NA-ACCORD Investigators. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009; 360: 1815-1826. doi:10.1056/ NEJMoa0807252 PubMed
5. Brasil. Ministério da Saúde. Recomendações para terapia antiretroviral em adultos infectados pelo HIV. Secretaria de Vigilância em Saúde. Programa Nacional de DST e Aids. 2008; p. 244.
6. Kelly JA, Kalichman SC. Behavioral research in HIV/AIDS primary and secondary prevention: recent advances and future directions. J Consult Clin Psychol. 2002; 70: 626-639. doi:10.1037/0022-006X.70.3.626 PubMed
7. Nemes MI, Carvalho HB, Souza MF. Antiretroviral therapy adherence in Brazil. AIDS. 2004; 18 (Suppl 3): S15-S20. doi:10.1097/00002030-200406003-00004 PubMed
8. Seidl EM, Melchíades A, Farias V, Brito A. [Persons living with HIV/AIDS: factors associated with adherence to antiretroviral treatment]. Cad Saude Publica. 2007; 23: 2305-2316. PubMed doi:10.1590/S0102-311X2007001000006
9. Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 2010; 85: 1-18. doi:10.1016/j.antiviral. 2009.10.002 PubMed
10. Lesho EP, Gey DC. Managing issues related to antiretroviral therapy. Am Fam Physician. 2003; 68: 675-686. PubMed
11. Woldemedhin B, Wabe NT; The Reason for Regimen Change Among HIV/AIDS Patients Initiated on First Line Highly Active Antiretroviral Therapy in Southern Ethiopia. N. Am J Med Sci. 2012; 4: 19-23.
12. Nachega JB, Mugavero MJ, Zeier M, Vitória M, Gallant JE. Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs. Patient Prefer Adherence. 2011; 5: 357-367. doi:10.2147/PPA.S22771 PubMed
13. Burgoyne RW, Tan DH. Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act. J Antimicrob Chemother. 2008; 61: 469-473. doi:10.1093/jac/dkm499 PubMed
14. Max B, Sherer R. Management of the adverse effects of antiretroviral therapy and medication adherence. Clin Infect Dis. 2000; 30 (Suppl 2): S96-S116. doi:10.1086/313859 PubMed
15. Subbaraman R, Chaguturu SK, Mayer KH, Flanigan TP, Kumarasamy N. Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis. 2007; 45: 1093-1101. doi:10.1086/521150 PubMed
16. Vidal F, Domingo P, Viladés C, Peraire J, Arnedo M, Alcamí J, Leal M, Villarroya F, Gatell JM. Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy. Expert Opin Drug Metab Toxicol. 2011; 7: 1365-1382. doi:10.1517/174252 55.2011.621941 PubMed
17. Lochet P, Peyrière H, Lotthé A, Mauboussin JM, Delmas B, Reynes J. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med. 2003; 4: 62-66. doi:10.1046/j.1468-1293.2003.00136.x PubMed
18. Reisler K. High hepatotoxicity rate seen among HAART patients. Aids Alert. 2001; 16: 118-119. PubMed
19. Bartlett JA, Fath MJ, Demasi R, Hermes A, Quinn J, Mondou E, Rousseau F. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS. 2006; 20: 2051-2064. doi:10.1097/01. aids.0000247578.08449.ff PubMed